title: How I treat late effects in adults after allogeneic stem cell transplantation.
abstract: More than 25,000 allogeneic hematopoietic stem cell transplantations (allo-HCTs) are expected to be performed worldwide in 2010, a number that has been increasing yearly. With broadening indications, more options for allo-HCT, and improvement in survival, by 2020 there may be up to half a million long-term survivors after allo-HCT worldwide. These patients have increased risks for various late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring recommendations for this patient population. The purpose of this article is to describe practical approaches to screening for and managing these late effects, with the goal of reducing preventable morbidity and mortality associated with allo-HCT.
authors.affiliation: Long-Term Follow-up Transplant Clinic, Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA. Bipin.Savani@Vanderbilt.Edu
authors.forename: Bipin N
authors.initials: BN
authors.lastname: Savani
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Griffith
authors.forename: Shubhada
authors.initials: S
authors.lastname: Jagasia
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Lee
mesh_terms: D000328:Adult; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D017741:Survivors; D013997:Time Factors; D014184:Transplantation, Homologous / Q000009:adverse effects; D014611:Vaccination